Clinical trial
Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study
NCT02249676 is registered in ClinicalTrials.gov with Tianjin Medical University General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study
- Lead sponsor
- Tianjin Medical University General Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2013
- Completion date
- December 31, 2014
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
devic disease, devic syndrome, devic's disease, devic's neuromyelitis optica, devic's syndrome